Cormorant Asset Management LP 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 3:02 pm Sale | 2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Cormorant Asset Management LP | 0 0.000% | -2,893,717 (Position Closed) | Filing |
| 2023-02-14 3:11 pm Sale | 2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Cormorant Asset Management LP | 2,893,717 5.980% | -108,483 (-3.61%) | Filing |
| 2022-02-14 3:08 pm Sale | 2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Cormorant Asset Management LP | 3,002,200 6.460% | -191,774 (-6.00%) | Filing |
| 2021-07-08 4:02 pm Purchase | 2021-06-28 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Cormorant Asset Management LP | 3,193,974 7.180% | 3,193,974 (New Position) | Filing |